Legal Advantage Investments’s Revolution Medicines RVMD Stock Holding History

Legal Advantage Investments’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$375K	Buy	+2,000	New	+$292K	0.13%	68

Other funds holding RVMD

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Legal Advantage Investments's RVMD Position: Q2 2026 in Review

Legal Advantage Investments opened a new position in Revolution Medicines (RVMD) in Q2 2026: 2,000 shares worth $375K. The stake represents 0.13% of the portfolio and ranks #68 among its holdings.

208 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Legal Advantage Investments held 2,000 shares of Revolution Medicines worth $375K as of Q2 2026.
Revolution Medicines was a new Legal Advantage Investments position in Q2 2026.
Revolution Medicines made up 0.13% of Legal Advantage Investments's portfolio in Q2 2026, its #68 holding.
208 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Legal Advantage Investments's 13F filing for Q2 2026, filed 15 Jul 2026.